Article Text

Download PDFPDF
Time for transparency
  1. David Phizackerley, DTB Deputy Editor
  1. BMJ, London, UK
  1. Correspondence to David Phizackerley, BMJ, London, UK; dphizackerley{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In July 2020, the Independent Medicines and Medical Devices Safety Review (IMMDSR) team published the findings of its investigation into the avoidable harm caused by hormone pregnancy tests, sodium valproate and pelvic mesh implants.1 Baroness Cumberlege, who chaired the review, concluded, ‘the healthcare system—in which I include the NHS, private providers, the regulators and professional bodies, pharmaceutical and device manufacturers, and policymakers—is disjointed, siloed, unresponsive and defensive. It does not adequately recognise that patients are its raison d’etre’. One of the report’s nine recommendations focused on financial links between companies that produce drugs and medical devices, and clinicians, hospitals and other organisations. The IMMDSR team were particularly concerned over the lack of transparency, and included a plea from a group representing patients that ‘we should be aware of clinicians’ allegiances or involvements whether they be financial or other’.1 …

View Full Text


  • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

  • Provenance and peer review Commissioned; externally peer reviewed.